[Systemic therapy of atopic dermatitis].
The optimal treatment of atopic dermatitis requires regular medical supervision. The course of this chronic skin disease is influenced by multiple triggers which are relevant for the treatment. The mainstays of topical therapy include regular use of emollients coupled with antimicrobial substances, corticosteroids and immune modulators as required. Ultraviolet radiation and immunosuppressive regimens represent further options for the treatment of severe exacerbations and may lead to long term improvement. Data from experimental studies provide insight into possible future treatment methods.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D018592:Cross-Over Studies; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000628:therapy*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D004195:Disease Models, Animal; D004311:Double-Blind Method; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007223:Infant; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D008516:Medicine, Chinese Traditional; D051379:Mice; D008819:Mice, Nude; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009824:Ointments; D011701:PUVA Therapy; D017893:Photopheresis; D010789:Phototherapy; D010919:Placebos; D019936:Probiotics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D014467:Ultraviolet Therapy
D000276:Adjuvants, Immunologic; D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D000935:Antifungal Agents; D003879:Dermatologic Agents; D006633:Histamine Antagonists; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D020024:Leukotriene Antagonists; D009824:Ointments; D010919:Placebos; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine